UNSPSC 51123601: Amiodarone

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C25H29I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) N3RQ532IUT, chemically known as 2-n-butyl-3,5-diiodo-4-n-diethylaminoethoxy-3-benzoylbenzofuran but more generally known as amiodarone, which bears US NIH Compound Identifier 2157. Amiodarone most often comes in base and hydrochloride forms.

UNSPSC 51123601 Amiodarone (Commodity) addresses pharmaceutical supply for emergency medical and healthcare settings, with recent state and local solicitations buying advanced life support medications, generic multi-source pharmaceuticals for statewide distribution, and direct-to-manufacturer prescription fulfillment capabilities. The City of Tampa Fire Rescue procured specific intravenous medications including epinephrine, adenosine, diltiazem, and labetalol through sealed competitive bidding; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) established framework contracts for generic and OTC pharmaceutical products across multiple states through authorized wholesalers; and the Texas Health and Human Services Commission issued a market research request to explore direct-manufacturer prescription programs outside traditional pharmacy benefit manager channels. State and local issuing bodies—city fire and emergency services, state health and human services departments, and multi-state cooperative purchasing entities—are the primary buyers under this code, with healthcare agencies and emergency medical services as end users. Vendors must comply with FDA manufacturing and labeling requirements, maintain expiration dates and shelf-life minimums, provide Safety Data Sheets per OSHA standards, and hold appropriate liability insurance; cooperative purchasing vehicles and framework contracts structure much of the activity.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's sealed-bid procurement (IFB No. 26P00188, due April 8, 2026, estimated value $40,000) required four specific medication line items with nine-month minimum expiration dates, firm pricing including freight-on-board delivery within ten calendar days, and a five percent bid discount for Small Local Business Enterprise participation. The Minnesota MMCAP RFP (due March 26, 2026) sought manufacturers of generic pharmaceuticals and OTC products for statewide and multi-state distribution through three authorized wholesalers, with awards effective July 1, 2026, evaluation weighted 75 percent on price competitiveness and contract terms through June 30, 2028 or later. The Texas HHS Commission's April 2026 Request for Information explored vendor capability for direct-to-manufacturer contracting models outside traditional PBM and GPO channels, signaling state-level interest in alternative pharmaceutical supply and pricing strategies. Cooperative purchasing vehicles and multi-state frameworks dominate the landscape alongside direct municipal procurement.